Insider Buying: Rhythm Pharmaceuticals Inc (RYTM) Insider Purchases $15,045,000.00 in Stock

Rhythm Pharmaceuticals Inc (NASDAQ:RYTM) insider Bros. Advisors Lp Baker purchased 885,000 shares of the business’s stock in a transaction dated Thursday, October 5th. The shares were bought at an average price of $17.00 per share, with a total value of $15,045,000.00. The purchase was disclosed in a document filed with the SEC, which is available through the SEC website.

Shares of Rhythm Pharmaceuticals Inc (RYTM) opened at 25.25 on Monday. Rhythm Pharmaceuticals Inc has a 1-year low of $23.21 and a 1-year high of $33.81. The company’s market capitalization is $658.37 million.

TRADEMARK VIOLATION NOTICE: “Insider Buying: Rhythm Pharmaceuticals Inc (RYTM) Insider Purchases $15,045,000.00 in Stock” was originally posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this article on another website, it was copied illegally and republished in violation of US and international copyright and trademark laws. The legal version of this article can be viewed at https://ledgergazette.com/2017/10/09/insider-buying-rhythm-pharmaceuticals-inc-rytm-insider-purchases-15045000-00-in-stock.html.

About Rhythm Pharmaceuticals

Rhythm Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of peptide therapeutics for the treatment of rare genetic deficiencies that result in life-threatening metabolic disorders. The Company’s lead peptide product candidate is setmelanotide, a potent, first-in-class melanocortin-4 receptor, or MC4R, agonist for the treatment of rare genetic disorders of obesity.

Receive News & Ratings for Rhythm Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rhythm Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply